Cargando…

Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation

Pharmacologic management of atrial fibrillation (AF) is a pressing problem. This arrhythmia afflicts >5 million individuals in the United States and prevalence is estimated to rise to 12 million by 2050. Although the pill-in-the-pocket regimen for self-administered AF cardioversion introduced ove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verrier, Richard L., Belardinelli, Luiz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of Cardiovascular Pharmacology 2020
Materias:	Invited Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161718/ https://www.ncbi.nlm.nih.gov/pubmed/32032206 http://dx.doi.org/10.1097/FJC.0000000000000804

Ejemplares similares

Emerging Antiarrhythmic Drugs for Atrial Fibrillation
por: Saljic, Arnela, et al.
Publicado: (2022)

Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation
por: Verrier, Richard L., et al.
Publicado: (2013)

Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging
por: Dan, Gheorghe-Andrei, et al.
Publicado: (2018)

Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation
por: Reiffel, James A.
Publicado: (2018)

Comparison of Circumferential Pulmonary Vein Isolation and Antiarrhythmic Drug Therapy in Patients with Atrial Fibrillation
por: Xu, Yanmin, et al.
Publicado: (2012)

Prior antiarrhythmic drug use and the outcome of atrial fibrillation ablation
por: Winkle, Roger A., et al.
Publicado: (2012)

Computational Modeling for Antiarrhythmic Drugs for Atrial Fibrillation According to Genotype
por: Hwang, Inseok, et al.
Publicado: (2021)

Investigational Anti–Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?
por: Burashnikov, Alexander
Publicado: (2020)

Corrigendum: Computational modeling for antiarrhythmic drugs for atrial fibrillation according to genotype
por: Hwang, Inseok, et al.
Publicado: (2022)

Non-traditional antiarrhythmic drugs as upstream and downstream dam for atrial fibrillation burden
por: Dan, Gheorghe-Andrei
Publicado: (2020)

Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease
por: Pantlin, Peter G., et al.
Publicado: (2020)

Sex difference in atrial fibrillation recurrence after catheter ablation and antiarrhythmic drugs
por: Park, Yoon Jung, et al.
Publicado: (2023)

Clinical implications from the European Heart Rhythm Association consensus document on antiarrhythmic drug therapy
por: Özcan, Emin Evren, et al.
Publicado: (2018)

Atrial fibrillation
por: Munger, Thomas M., et al.
Publicado: (2014)

Evaluation of Index of Cardio-Electrophysiological Balance in Patients With Atrial Fibrillation on Antiarrhythmic-Drug Therapy
por: Afsin, Abdulmecit, et al.
Publicado: (2021)

US Antiarrhythmic Drug Treatment for Patients With Atrial Fibrillation: An Insurance Claims–Based Report
por: Tardos, Jonathan G., et al.
Publicado: (2021)

Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation
por: Heijman, Jordi, et al.
Publicado: (2013)

Intravenous Magnesium Sulfate Reduces the Need for Antiarrhythmics during Acute-Onset Atrial Fibrillation in Emergency and Critical Care
por: Gilardi, Emanuele, et al.
Publicado: (2022)

Resource use and clinical outcomes in patients with atrial fibrillation with ablation versus antiarrhythmic drug treatment
por: Jarman, Julian W. E., et al.
Publicado: (2018)

Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms
por: Geng, Meng, et al.
Publicado: (2020)

Correction to: Evaluation of Index of Cardio-Electrophysiological Balance in Patients With Atrial Fibrillation on Antiarrhythmic-Drug Therapy
por: Afsin, Abdulmecit, et al.
Publicado: (2021)

Meta‐analysis of cryoballoon ablation versus antiarrhythmic drugs as initial therapy for symptomatic atrial fibrillation
por: Mao, Yin‐jun, et al.
Publicado: (2021)

Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation
por: Kuniss, Malte, et al.
Publicado: (2021)

Heart failure risk in patients with atrial fibrillation treated with catheter ablation vs antiarrhythmic drugs
por: Gruber, Megan, et al.
Publicado: (2023)

Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design
por: Packer, Douglas L., et al.
Publicado: (2018)

Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation
por: Wang, Amy
Publicado: (2012)

Time‐dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses
por: Carstensen, Helena, et al.
Publicado: (2018)

Knots to untie: anticoagulant and antiarrhythmic therapy after ablation for atrial fibrillation
por: Stazi, Filippo
Publicado: (2020)

Atrial Fibrillation Induced by Anticancer Drugs and Underling Mechanisms
por: Burashnikov, Alexander
Publicado: (2021)

RAAFT-2: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Revisiting the Role of Antiarrhythmic Drugs in Prevention of Atrial Fibrillation Recurrence: A Single Center Retrospective Review
por: Mascarenhas, Daniel AN, et al.
Publicado: (2018)

Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study
por: Al-Jazairi, Meelad I H, et al.
Publicado: (2021)

Antiarrhythmic drug therapy after catheter ablation for atrial fibrillation—Insights from the German Ablation Registry
por: Schleberger, Ruben, et al.
Publicado: (2021)

Ablation and antiarrhythmic drug effects on PITX2(+/−) deficient atrial fibrillation: A computational modeling study
por: Jin, Ze, et al.
Publicado: (2022)

Atrial Tachycardias Arising from Ablation of Atrial Fibrillation: A Proarrhythmic Bump or an Antiarrhythmic Turn?
por: Shah, Ashok J., et al.
Publicado: (2010)

Effects of antiarrhythmics on atrial high rate episodes and progression to clinical atrial fibrillation (ANTI-AHRE)
por: Simovic, S, et al.
Publicado: (2023)

Antiarrhythmic and Electrophysiologic Effects of Flecainide on Acutely Induced Atrial Fibrillation in Healthy Horses
por: Haugaard, M.M., et al.
Publicado: (2014)

Undiagnosed sleep apnea in patients with atrial fibrillation: An underutilized opportunity for antiarrhythmic management
por: Hereijgers, Maartje J.M., et al.
Publicado: (2022)

Novel Pulmonary Delivery of Drugs for the Management of Atrial Fibrillation
por: Islam, Nazrul, et al.
Publicado: (2022)

Screening for atrial fibrillation: less is more?
por: Svennberg, Emma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bvp8oidi4sckmlei5jn17cfva9